Olaparib, rucaparib, and niraparib are three inhibitors of poly(ADP-ribose) polymerase (PARP) enzymes that have been recently approved for the treatment of ovarian cancer. The current article reviews the patent and journal literature regarding synthetic routes and final forms of these PARP inhibitors.

中文翻译：

---

最近批准的PARP抑制剂的生产路线专利审查：奥拉帕里布，鲁卡帕里布和尼拉帕里布

Olaparib，rucaparib和niraparib是聚（ADP-核糖）聚合酶（PARP）酶的三种抑制剂，最近已被批准用于治疗卵巢癌。当前文章回顾了有关这些PARP抑制剂的合成途径和最终形式的专利和期刊文献。